Buradasınız

Anasayfa » Content

Kronik Periton Diyalizi ve Hemodiyaliz Hastalarında Homosistein ve CRP

Homocysteine and CRP in Chronic Peritoneal Dialysis and Hemodialysis Patients

Journal Name:

  • Türk Nefroloji, Diyaliz ve Transplantasyon Dergisi

Publication Year:

  • 2007

Key Words:

Keywords (Original Language):

Author Name
Abstract (2. Language): 
Purpose: Cardiovascular diseases are the most common causes of morbidity and mortality in chronic renal failure patients. Homocysteine and CRP levels are considered as independent risk factors for cardiovascular disease. We aimed to determine homocysteine, CRP levels and lipid profile in peritoneal dialysis and hemodialysis patients. Method: Forty chronic peritoneal dialysis patients and 38 hemodialysis patients were selected by random sampling among patients followed in our clinic and were included in the study. Serum homocysteine, total cholesterol, triglyceride, LDL-cholesterol, HDL-cholesterol, vitamin 612, folic acid, albumin and CRP levels were measured. Findings: No significant differences were found between two groups in terms of homocysteine, CRP levels and lipid profile. Homocysteine level was high in 67.5% of PD and 78.9% of HD patients. CRP level was high (ratio of being over 3 mg/L] in 80% of PD and 74% of HD patients. Conclusion: Our data have revealed that chronic renal failure (CRF) patients being treated both with hemodialysis or peritoneal dialysis had increased risks with regard to homocysteine and CRP levels. No significant effects of treatment modality have been found on homocysteine and CRP levels.
Bookmark/Search this post with
Abstract (Original Language): 
Amaç: Kronik böbrek yetmezlikti (KBY) hastalarda kardiyovas-küler hastalıklar (KVH|, morbidite ve mortalitenin en Önemli nedenidir. Homosistein ve CRP düzeyleri, kardiyovasküler hastalık için bağımsız birer risk faktörü olarak kabul edilmektedir. Çalışmamızda periton diyalizi ve hemodiyaliz hastalarında homosistein, CRP ve lipid profili düzeylerini belirlemeyi amaçladık. Yöntem: Kliniğimizde takip edilen 40 kronik periton diyalizi (PD) ve 38 hemodiyaliz (HD) hastası çalışmaya alındı. Hastaların serumlarında homosistein, total kolesterol, trigliserit, LDL-kolesterol, HDL-kolesterol, Vitamin 812, folik asit, serum albümin ve CRP düzeyleri ölçüldü. Bulgular: Homosistein, CRP ve lipid profili ortalamaları açısından iki grup arasında anlamlı fark saptanmadı. Homosistein düzeyi PD grubundaki hastalarda %67.5, HD grubunda %78.9 oranında yüksek bulundu. CRP düzeyi açısından yüksek risk olarak kabul edilen 3 mg/L'nin üzerinde olma oranı ise PD grubunda %80, HD grubunda %74 idi. Sonuç: Çalışmamızda, hemodiyaliz ve periton diyalizi ile tedavi edilmekte olan kronik böbrek yetmezlikli hastalarda homosistein ve CRP düzeyleri benzer düzeylerde yüksek saptandı. Tedavi modalite-sinin homosistein ve CRP düzeylerine anlamlı etkisi saptanmamıştır.
FULL TEXT (PDF): 
PDF icon arastrmx_172977_16_pp_73-76.pdf
  • 2
73-76
  • Turkish

REFERENCES

References: 

1. Ma KW. Greene EL. Raij L Cardiovascular risk factors in chronic renal failure and hemodialysis populations. Am J Kidney Dis 1992;19:505-13.
2. Cases A, Vera M, Lopez GjM. Cardiovascular risk in patients with chronic renal failure. Nefrologia 2002;22:68-74.
£ Hayes B, Pastor C, Bonal J, Junt a J, Hernandez JM, Riutort N, Forastcr A. Romero R. Homocysteine, C-reactive protein, lipid peroxidation and mortality in haemodialysis patients. Nephrol Dial Transplant 2003:IK: 106-12.
4, Okluuna T. Minagawa '1', Takada N, Ohno M, Oda H, Ohas-hi H. C-reactive protein. Lipoprotein (a), homocysteine, and male sex contribute to carotid atherosclerosis in peritoneal dialysis patients. Am J Kidney Dis 2003;42:355-61.
5, Arici M, Walls J. End-stage renal disease, atherosclerosis and cardiovascular mortality; Is C-reactive protein the missing link> Kidney Int 2001:59:4(>~-14.
6, Durand P, Prost M, Loreau IN. Ltıssier-Cacan S, Blache D. Impaired homocysteine metabolism and atherothromhotic disease. Lab Invest 200I;81:64=5-72.
7, Bostom AC Silbersharz H, Rosenberg IH, Selhub J, D'Agos-tino RI5. Wolf PA, Jacques PL, Wilson PWF. Nonfasting plasma total homocysteine levels and all-cause and cardiovascular disease mortality in elderly Framingham men and women. Arch Intern Med 1999:159: lO"? 80.
S. Welch GN, Loscalzo J. Homocysteine and aiherothrombosis. N Engl J Med 1998;338:1042-50.
9, Friedewald WT, Levy Rl, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18:499-502.
10. Boston! AG. Lathrop L. 1 lyperhoniocysteinemia in end stage renal disease: Prevalence, etiolfjgy and potenlial relalionship
to arteriosclerotic outcomes. Kidney int 1997;52:10-20.
11. Bostom AG, Culleton BF. Hyperhomocysteinemia in chronic renal disease. J Am Soc Nephrol 1999;10:891-900.
12. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998;32:112-119.
13. Friedman AN, Bostom AG, Selhub J, Levey AS, Rosenberg III. The kidney and homocysteine metabolism. J Am Soc Nepli-rol 2001;12:2181-89.
14. Van Guldener C, Slam F. Stehower CD. Homocysteine metabolism in renal failure. Kidney Int 2001;78:234-7.
15. Bostom AG, Laltraup L. Hyperhomocysteinemia in end stage renal disease: prevalence, etiology, and potential relationships to atherosclerotic outcomes. Kidney Int 1997;52:10-20.
16. Fellah H, Feki M, Hsairi M, Sanhajİ H, Kaabachi N, Alxlallali TB, et al. Hyperhomocysteinemia and end-stage renal disease: determinants and association with cardiovascular disease in Tunisian patients, Clin Chem Lab Med 2003;41:675-80.
17. Robinson K, Gupta A, Dennis V, Arheart K, Chaudhary D, Green R, et al. Hyperhomocysteinemia confers an independent risk of atherosclerosis in end-stage renal disease and closely linked to plasma folate and pyridoxine concenlrali-ons. Circulation 1996;94:2743-8.
18. Eikelboom JW, Hankey GJ. Associations of homocysteine, C-reactive protein and cardiovascular disease in patients with renal disease. Curr Opin Nephrol Hypertens 2001;15:81-91.
19. Klusmann A, Ivens K, Schadewaldt P, Grabensee R, fleering P. Is homocysteine a risk factor for coronary heart disease in patients with terminal renal failure? Med Klin 2000; 95:189-94.
20. Suliman MF,., Stenvinkel P, Barany P, Heimburger O, Anders-tam B, Lindholm B. Hyperhomocysteinemia and its relationship to cardiovascular disease in ESRD: influence of hypoal-buminemia. malnutrition, inflammation, and diabetes melli-tus. Am J Kidney Dis 2003;41:89-95.
21. Yılmaz FM, Yılmaz G, Duranay M, Parpucu H, Şeneş M, Tekeli N, Yücel D. Cardiovascular risk factors in hemodialysis and peritoneal dialysis patients. Scant! J Clin Lab Invest 2005: 65(8):739-45.
22. Yeun JY, Levine RA, Mantadilok V. Kaysen GA. C-reactive protein predicts all cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 2000;35:469-76.
23. Bassuk SS, Rifai N, Ridker PM. High-sensitivity C-reactive protein: clinical importance. Curr Probl Cardiol. 2004;29:439-93.
24. Nam BH, Kannel WB, D'Agostino RK Search for an optimal atherogenic lipid risk profile: from the Framingham Study. Am J Cardiol. 2006;97(3):372-5.
25. Natarajan S, GHck H, Criqui M, Horowitz D, Lipsitz SR, Ki-nosian B. Cholesterol measures to identify and treat individuals at risk lor coronary heart disease. Am J Prev Metl. 2003;25(D:50-7.
26. Kinosian B, Click H, Garland G. Cholesterol and coronary heart disease: predicting risks by levels and ratios. Ann Intern Med. 1994;12K9):64l-7.

Thank you for copying data from http://www.arastirmax.com